J Rheumatol 2021 Apr 1. Epub 2021 Apr 1.
Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care, London, Canada; Boehringer Ingelheim (Canada) Limited, Burlington, Canada; HOPE Research Centre, Sunnybrook Research Institute, Toronto, Canada; Dept of Respiratory Medicine, Pathology and Molecular Medicine, McMaster University, Hamilton, Canada. Funding for this study was provided by Boehringer-Ingelheim (Canada) Limited. Pope JE has undertaken consultancy work for AbbVie, Actelion, Baxter, Bayer, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Quansah K and Flavin J are employees of Boehringer Ingelheim Canada Limited. Hassan S and Seung SJ received unrestricted funding from Boehringer Ingelheim Canada Limited. Kolb M reports grants and personal fees from Roche, Boehringer Ingelheim and Prometic, personal fees from Gilead and Genoa, and grants from Actelion, Respivert, Alkermes and Pharmaxis. Address correspondence to Dr. Janet E Pope, St Joseph's Health Care, 268 Grosvenor St., Rheumatology D2, London, Ontario, Canada, N6G 2S3. E-mail:
Objective: Systemic sclerosis (SSc) is a rare autoimmune disease. Pulmonary complications of SSc are one of the leading causes of morbidity and mortality. The objective of this study was to determine prevalence and survival estimates of SSc and SSc-ILD in a Canadian province (Ontario) using administrative data over 10 years. Read More